Endo International plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENDP research report →
About the company
Endo International plc operates as a specialty pharmaceutical firm, developing and marketing both proprietary brand-name and unbranded generic medications across the United States and global markets. Its Branded Pharmaceuticals division offers a diverse array of prescription products, notably including XIAFLEX for the treatment of Dupuytren's contracture in adults, SUPPRELIN LA to address central precocious puberty in children, NASCOBAL nasal spray for managing vitamin B12 deficiency, and AVEED for hypogonadism. Other significant branded offerings encompass QWO, an injectable solution for moderate to severe cellulite in adult women's buttocks; PERCOCET for moderate to moderately-severe pain; TESTOPEL, an implantable pellet indicated for testosterone replacement therapy (TRT); EDEX for erectile dysfunction; and LIDODERM, a topical patch designed to alleviate pain.
- CEO
- Blaise Coleman
- IPO
- 2014
- Employees
- 3,103
- HQ
- Dublin, US
Price Chart
- Market Cap
- $0
- P/E
- -0.15
- P/S
- 0.00
- P/B
- -0.07
- EV/EBITDA
- 6.22
- Div Yield
- 0.00%
- Gross Margin
- 59.21%
- Op Margin
- 0.53%
- Net Margin
- -19.01%
- ROE
- 60.16%
- ROIC
- 0.22%
- Revenue
- $2.99B · 3.10%
- Net Income
- $-569,081,000 · -409.38%
- EPS
- $-2.44 · -408.86%
- Op Income
- $15.75M
- FCF YoY
- 202.79%
- Beta
- 1.15
Get TickerSpark's AI analysis on ENDP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 22 | Tursi James Patrick | sell | 280,373 |
| Mar 30, 22 | Barry Patrick A | other | 42,341 |
| Mar 29, 22 | Barry Patrick A | other | 16,957 |
| Mar 30, 22 | Barry Patrick A | other | 4,975 |
| Mar 29, 22 | Barry Patrick A | other | 4,141 |
| Mar 29, 22 | Raciti Frank B. | other | 965 |
| Mar 29, 22 | Maletta Matthew Joseph | other | 34,414 |
| Mar 29, 22 | Maletta Matthew Joseph | other | 10,179 |
| Mar 30, 22 | Bradley Mark T. | other | 26,805 |
| Mar 29, 22 | Bradley Mark T. | other | 10,735 |
Our ENDP coverage
Recent articles, reports, and earnings notes.
No research on ENDP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENDP report →Similar companies
Peers in the same neighborhood.